Hormonal
Inflammation, marked by elevated C-reactive protein (CRP), white blood cells, and adhesion molecules, is a key nontraditional risk factor for CVD in diabetes, linked to insulin resistance and obesity.
Chronic, low-grade inflammation is a major driver of heart disease in diabetes, often stemming from excess body fat and insulin resistance. This inflammation damages blood vessels and promotes clotting. Strategies to reduce body weight and improve insulin sensitivity can lower inflammatory markers like CRP and reduce CVD risk.
Many of the risk factors identified may reflect underlying inflammation... Plasma CRP is elevated in obese subjects who have other features of the IRS... inflammation originating from excess adipose tissue cytokine production may contribute not only to the development of the IRS but also to the associated CVD.
Why this rating
Cited studies show CRP and other inflammatory markers are predictors of CVD and are elevated in insulin-resistant states.
Source
Nontraditional Risk Factors for Cardiovascular Disease in Diabetes
Vivian Fonseca et al. · Endocrine Reviews · 2004
DOI 10.1210/er.2002-0034
More from this paper
- Insulin resistance (IR) and hyperinsulinemia are independent, nontraditional risk factors for cardiovascular disease (CVD) in type 2 diabetes, contributing to excess morbidity and mortality beyond traditional risk factors like hypertension and dyslipidemia.Good
- Endothelial dysfunction, characterized by impaired nitric oxide (NO) production and increased asymmetric dimethylarginine (ADMA), is an early and independent predictor of cardiovascular events in diabetes, often preceding clinical symptoms.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →